We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

27 hedge funds and large institutions have $2.15M invested in Gyre Therapeutics in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

0.24% more ownership

Funds ownership: 0% → 0.24% (+0.24%)

7% less funds holding

Funds holding: 29 → 27 (-2)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

56% less capital invested

Capital invested by funds: $4.9M → $2.15M (-$2.75M)

Holders
27
Holders Change
-2
Holders Change %
-6.9%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
8
Increased
6
Reduced
4
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$158K
2
VKH
Virtu KCG Holdings
New York
+$30.6K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$18.8K
4
TSS
Two Sigma Securities
New York
+$18K
5
UBS Group
UBS Group
Switzerland
+$16.2K

Top Sellers

1
BI
BVF Inc
California
-$1.05M
2
DCM
DAFNA Capital Management
California
-$86K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$81.8K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$72K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$30K
Name Holding Trade Value Shares
Change 		Change in
Stake
EWM
1
Essex Woodlands Management
Texas
$778K – – –
NMC
2
NEA Management Company
Maryland
$424K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$251K +$158K +1,760 +106%
UBS Group
4
UBS Group
Switzerland
$243K +$16.2K +180 +6%
BIT
5
BlackRock Institutional Trust
California
$92K -$9.8K -109 -8%
Vanguard Group
6
Vanguard Group
Pennsylvania
$67K -$81.8K -909 -50%
IP
7
Intellectus Partners
California
$61K +$75.5K +839 New
CCM
8
Colorado Capital Management
Colorado
$50K – – –
Goldman Sachs
9
Goldman Sachs
New York
$31K +$4.68K +52 +14%
VKH
10
Virtu KCG Holdings
New York
$25K +$30.6K +340 New
WS
11
Wedbush Securities
California
$24K +$12.8K +142 +76%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$16K +$90 +1 +0.4%
Citadel Advisors
13
Citadel Advisors
Florida
$16K +$4.41K +49 +30%
TSS
14
Two Sigma Securities
New York
$15K +$18K +200 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$15K +$18.8K +209 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$11K -$180 -2 -1%
Millennium Management
17
Millennium Management
New York
$11K +$13K +145 New
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$9K – – –
ARTA
19
A.R.T. Advisors
New York
$6K +$8.28K +92 New
PAM
20
Panagora Asset Management
Massachusetts
$1K – – –
BI
21
BVF Inc
California
– -$1.05M -7,696 Closed
DCM
22
DAFNA Capital Management
California
– -$86K -630 Closed
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
– -$72K -526 Closed
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
– -$30K -219 Closed
NMIMC
25
Northwestern Mutual Investment Management Company
Wisconsin
– -$28K -205 Closed
1
2

GYRE Hedge Fund Activity: Q4 2016 in Review

27 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2016, worth a combined $2.15M — down 56% from $4.9M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of GYRE and 8 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $158K. The largest seller was BVF Inc, exiting entirely with an estimated $1.05M sold.

  • 27 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2016, down from 29 in Q3 2016.
  • Funds reported $2.15M of Gyre Therapeutics stock for Q4 2016, down 56% quarter-over-quarter.
  • 8 funds opened new Gyre Therapeutics positions in Q4 2016 and 9 closed out, a net change of -1 holder.
  • The largest Gyre Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $158K added.
  • The largest Gyre Therapeutics seller in Q4 2016 was BVF Inc, an estimated $1.05M sold.

Based on aggregated 13F filings for Q4 2016.